Separase (extra spindle poles-like 1), a cysteine protease and endopeptidase, has a central role in cell cycle progression in ensuring immaculate genetic inheritance. In the normal cell, activation of separase initiates anaphase at two diligently controlled consecutive events ([@bib22]; [@bib10]; [@bib18]; [@bib42]). In the first event, separase triggers the cleavage of the Scc1/Rad21 subunit of cohesin, thus inactivating the complex. In the next event, separase participates in the final unleashing of the sister-chromatids at anaphase onset ([@bib34]; [@bib31]). Abnormally increased proteolytic activity of separase has been described to predispose the cell to uncontrolled centriole duplication, chromosomal missegregation and aneuploidy ([@bib25]; [@bib9]). Owing to its central role in metaphase--anaphase transition, both premature and delayed activation of separase will result in chromosomal instability ([@bib42]).

Separase is tightly and in a mutually exclusive manner regulated by complex inhibitory interactions in pathways involving either securin (pituitary tumour-transforming gene 1 protein) or cyclin B1/CDK1 (G2 mitotic-specific cyclin-B1/cyclin-dependent kinase 1) ([@bib42]). In both of these pathways, the proteolytic activation of separase is dependent on ubiquitin-dependent degradation of either securin or cyclin B1 ([@bib12]; [@bib38]; [@bib11]). Securin, an anaphase inhibitor, forms with separase a complex with ability to arrest the cell cycle at metaphase. Ubiquitin-dependent destruction of this link results in activation of separase triggering premature sister chromatid separation ([@bib12]). In addition, separase activity is controlled by cyclin B1 complex promoting dissociation of sister chromatid separation ([@bib10]). Both of these events are mediated by the anaphase-promoting complex/cyclosome (APC/C) promoting the destruction of securin and cyclin B1 ([@bib33]). Uncontrolled inhibition of separase activity by either securin or cyclin B1 will result in uncontrolled and premature segregation of the sister chromatids and hamper immaculate genetic inheritance, the cornerstone event of malignant development ([@bib41]).

Previously, overexpression and variation in subcellular localisation of separase have been reported in specific types of human malignancies, including breast carcinomas ([@bib19]; [@bib43]; [@bib21]; [@bib42]). Although the role of separase as an oncogene and in promoting aneuploidy and genetic heterogeneity is well established ([@bib42]), the different expression patterns, associations with clinically applied proliferation markers or prognostic associations of separase have not previously been described in a large breast carcinoma material with long-term follow-up. In the present study, we demonstrate separase expression in a 349 breast carcinoma patients with a maximum of \>22-year follow-up. Based on double- and triple-immunofluorescence (IF) stainings, we also describe the co-expressions and discuss the possible roles of securin and cyclin B1 in regulation of separase expression in breast carcinomas. In our experience, separase is a promising proliferation marker that could be applied into clinical use in histopathology. Moreover, in comparison with the established clinical prognosticators, separase expression showed strong and independent prognostic value in breast carcinoma. In all, our results suggest that separase could be developed into a beneficial biomarker for treatment decisions in breast carcinoma, particularly for patients with luminal subtype.

Materials and methods
=====================

Patients and tissue materials
-----------------------------

The study comprises tissue specimen obtained from 349 female breast cancer patients. All patients were diagnosed and treated with unilateral invasive breast cancer in Central Hospital of Central Finland, Jyväskylä, Finland, during 1987--1997 ([Supplementary material Table 1](#sup1){ref-type="supplementary-material"}). All patients were treated with surgical resection or mastectomy with axillary evacuation, radiation and/or adjuvant treatment with anti-oestrogenic or cytostatic drugs depending on the patients' age, hormone receptor and lymph node status according to the international guidelines for breast cancer treatment at the time of diagnosis ([@bib6]). No pre-operative adjuvant treatments were administered. Complete clinical data were collected from pathology reports and patient files and registered applying the criteria presented by WHO ([@bib17]) and St Gallen International Expert Consensus ([@bib3]). Causes of death were obtained from autopsy reports, death certificates and from the national cancer registry (Statistics Finland, Helsinki, Finland) resulting in up to 22 years and 9 months follow-up period (median 12.4 years).

Separase immunohistochemistry (IHC) of breast cancer tissue was available from each of the 349 patient cases. Tissue materials for IHC and IF were prepared according to standard histology practice, that is, fixed in buffered formalin (pH 7.0) and embedded into paraffin blocks. TMAs were prepared by collecting from the representative tumour area of each patient two tissue cores, each 0.6 mm in diameter. Benign breast epithelium was observed outside carcinomas. In addition, normal breast tissue was obtained from core needle biopsies and breast reductions of healthy young individuals.

Staining methods
----------------

IHC was performed on sections cut at 3 *μ*m. For separase (mouse monoclonal, 6H6, Novus Biologicals, Littleton, CO, USA H00009700-M01, 1:300) we used Lab Vision Autostainer 480 (Thermo-Fisher Scientific, Fremont, CA, USA) with detection performed applying PowerVision+polymer kit with diaminobenzidine as chromogen (DPVB+110HRP; Immunovision Technologies, Vision Biosystems, Norwell, MA, USA) according to standard protocol. IHC of securin, Ki-67, oestrogen (ER) and progesterone (PR) receptors and HER2 were performed and interpreted as previously described ([@bib8]) and *HER2*-amplification status confirmed with *in situ* hybridisation (ISH) ([@bib3]).

For double-IF, sections were stained manually using a tyramide signal amplification system for the sequential detection of rabbit and mouse primary antibodies for separase and Ki-67, PHH3, securin, cyclin B1 and Cleaved caspase-3 as described previously ([@bib8]) ([Table 1](#tbl1){ref-type="table"}). Triple-IF was performed as double-IF, but secondary antibodies specific for species and immunoglobulin subtype were used in the detection ([Table 1](#tbl1){ref-type="table"}). Control stainings indicated no cross reactions between the used primary and secondary antibodies.

Interpretation of IHC and IF
----------------------------

In IHC of breast tissues, separase expression was observed both in the cytoplasm and in the nucleus of epithelial cells. First, we evaluated separase expression as intensive nuclear precipitates in mitotic cells. In each case, the number of separase-expressing mitotic figures was calculated in sets of one hundred cancer cells (minimum 100 and maximum 3 × 100 cancer cells evaluated) and registered as an average fraction (%) of separase-positive mitoses for each patient (so called mitotic separase). Second, the intensity of the overall separase-staining, so called diffuse separase expression, was evaluated in the cytoplasm and nucleus of cancer cells, and this was registered as negative (score 0) or positive ranging from faint to strong (1+--2+) (so called diffuse separase). Separase expression in the breast carcinoma specimen was evaluated as compared with the expression observed in benign breast epithelium of breast reduction specimen. Based on this comparison, we defined abnormal diffuse separase expression as loss of expression while abnormal mitotic expression was observed as increase in the number of immunopositive cells.

Immunoexpressions for securin and cyclin B1 were observed as combinations of nuclear and cytoplasmic staining and registered as average fractions (%) of positively staining cancer cells as presented previously ([@bib35]; [@bib15]). Interpretations for IHC of ER, PR, and IHC and ISH for HER2 followed previous literature and generally accepted international guidelines ([@bib7]; [@bib39]).

All IHC interpretations were performed by an experienced histopathologist (PK). Double- and triple-IF stainings combining separase with Ki-67, PHH3, securin, cyclin B1 and cleaved caspase-3 were scanned (Pannoramic Midi II scanner, 3dhistech, using automatic exposure time and ensuring no leakage of fluorescence labels between channels) and co-expressions of the studied proteins were evaluated both in microscopy and in virtually merged photomicrographs.

Statistical analysis
--------------------

Prognostic analyses were performed separately for mitotic and diffuse separase expressions and for both expression patterns optimal cut points were determined in univariate analyses. Concerning mitotic separase, patient cases were optimally stratified according to absence *vs* presence (\<1% *vs* ⩾1%) of separase-positive cancer cell mitoses. For diffuse separase expression (intensities 0--2+), the optimal cut point was identified between negative *vs* positive expression (0 *vs* 1+--2+). The categorisations were supported by morphological observations of separase-IHC in the breast carcinomas and in benign breast tissue. Categorisationof immunoexpressions of securin and cyclin B1 at 10% of positive cancer cells (\<10% *vs* ⩾10%) were based on previous literature ([@bib16]; [@bib35]).

Associations between categorised mitotic and diffuse separase and the other studied markers were analysed by Fisher's exact test and Pearson/Spearman correlation when handled numerically. Survival analyses for mitotic and diffuse separase expressions were first started with univariate analysis for time to breast cancer-specific death and estimated using the Kaplan--Meier technique with Wilcoxon tests. For further analysis involving multiple factors, we evaluated the prognostic value of mitotic and diffuse separase in relation to the established prognosticators of breast cancer that is, nodal status, tumour size, histological grading, and added with immunopositivities for Ki-67 and securin. The final analyses were performed with the help Cox proportional hazard models. Patients with missing data were automatically excluded from the analyses. Differences between categories were quantified by calculating hazard ratio (HRs) with 95% confidence interval (CI). *P*-values\<0.05 (two-tailed) were considered statistically significant. The statistical computations were performed using SAS System for Windows, version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results
=======

In IHC, separase expression in breast carcinoma could be observed as two distinct morphological patterns, first, in mitotic cells and, second, as diffuse expression in the cytoplasm and nucleus of cancer cells ([Figure 1](#fig1){ref-type="fig"}). In breast carcinoma, these staining patterns occured inversely related, that is, high mitotic separase expression was usually accompanied with lack of diffuse separase expression, an expression pattern particularly common in carcinomas showing aggressive morphological and clinical features. On the contrary, strong diffuse separase expression was associated with lack of mitotic separase in breast carcinoma cases exhibiting favourable histology and clinical behaviour. Benign breast epithelium showed diffuse nuclear and cytoplasmic separase but mitotic separase in only single cells. In the connective tissue cells of the surrounding stroma, separase expression was occasional and faint.

In [Figure 2](#fig2){ref-type="fig"}, separase expression is demonstrated in double-IF stainings with proliferation markers Ki-67, PHH3 and securin, and apoptosis marker Cleaved caspase-3. In breast carcinoma, separase expression co-localised with PHH3 in the great majority (89.2%) of mitotic cancer cells. Instead, mitotic separase only partly co-localised with Ki-67-positive or securin-positive cancer cells (co-localisation observed in 53.3% and 62.9% of cancer cell mitoses, respectively).

In prognostic analyses, mitotic separase was a significant predictor of breast cancer death as demonstrated on basis of Kaplan--Meier curves calculated for disease-specific survival ([Figure 3](#fig3){ref-type="fig"}). In univariate approach, the presence of separase-positive mitoses (⩾1% of cancer cells) predicted a twofold risk of breast cancer death (*P*=0.0004, CI=1.4--3.0). Based on breast cancer-specific survival in the majority (\>75%) of breast carcinoma cases, we observed an 11.3-year survival difference between patient subgroups detected with and without separase-positive mitotic figures (4.3 and 15.6 years of survival for absence and presence of mitotic separase, respectively) ([Figure 3](#fig3){ref-type="fig"}). Kaplan--Meier analyses in subgroups of the intrinsic breast cancer classification also showed prognostic differences between cases detected with and without mitotic separase expression, however, statistically significant prognostic value could only be shown for the luminal subtype (HR 2.2, *P*=0.001, CI=1.4--3.4). Multivariate analyses involving mitotic separase and the established prognosticators of breast carcinoma, tumour size, histological grade and nodal status, are summarised in [Table 2](#tbl2){ref-type="table"}. When securin was added to the multivariate analysis, only securing -- and not separase -- was associated with statistically significant prognostic value indicating the superior prognostic value of securin over mitotic separase.

We also observed a significant prognostic value for the loss of diffuse separase expression in the breast carcinoma cases ([Figure 3](#fig3){ref-type="fig"}). Lack of diffuse separase expression in cancer cells indicated a 1.8-fold risk of breast cancer death (*P*=0.0006, CI 1.3--2.6) as compared with separase positivity (intensities 1+--2+). Also, we observed a significant survival difference between patient subgroups indicating that the majority (\>75%) of patients with carcinomas showing diffuse separase expression survived 12.5 years, whereas the patients with loss of diffuse separase expression only 4.9 years after primary diagnosis (*P*=0.001). In material divided into subgroups of intrinsic classification, only luminal carcinomas showed a statistically significant risk of breast cancer death associated with loss of diffuse separase expression (HR 2.9, *P*\<0.0001, CI 1.7--4.9) ([Figure 3](#fig3){ref-type="fig"}) whereas no prognostic association could be observed for Her2-amplified or triple-negative carcinomas (TNBC). In multivariate analysis involving the established clinical prognosticators of breast cancer, loss of separase expression showed independent prognostic value along with nodal status and tumour size (HR=1.8, *P*=0.002, CI 1.3--2.6) ([Table 2](#tbl2){ref-type="table"}). Finally, in a multivariate analysis involving both diffuse and mitotic separase, securin, Ki-67 and the established clinical prognosticators, loss of diffuse separase expression still remained an independent prognosticator for breast cancer death (HR 1.6, *P*=0.02, CI 1.1--2.4).

Finally, we wanted to contemplate the possible interactions between separase, securin and cyclin B1 in driving cancer cell proliferation in breast carcinoma. Based on statistical analysis of separase-IHC, mitotic separase was strongly associated with high expression levels of both securin (*P*\<0.0001) and cyclin B1 (*P*\<0.0001). To evaluate their expressions at the cellular level and make conclusions on their associations and possible mutual regulation in mitosis, we prepared double- and triple-IF stainings to demonstrate their co-expression in cells of breast carcinoma and benign breast epithelium. Double-IFs of breast carcinoma showed that separase-positive cells typically co-expressed cyclin B1 but not securin ([Figure 4](#fig4){ref-type="fig"}). This expression pattern resembles the one seen in normal breast epithelium, although owing to the low mitotic rate, the occurrence of positive cells in normal epithelium was naturally very rare. Instead, some carcinomas showed aberrant expression where cancer cells either co-expressed separase and securin or, alternatively, showed separase-positivity alone. These aberrant expression patterns were also verified in triple-IFs showing either the simultaneous expressions of the three markers or only separase expression in the same cancer cell ([Figure 4](#fig4){ref-type="fig"}).

Discussion
==========

Separase-IHC showed distinct prognostic value in our analysis involving 349 invasive breast carcinoma patients with a maximum of \>22-year follow-up. The prognostic value was obvious for both expression patterns observed for separase, that is, mitotic and diffuse separase. In our material, mitotic separase predicted a doubled risk of breast cancer death (*P*=0.0004) and predicted 11.3-year survival difference as calculated comparing the majority (\>75%) of patients with and without separase-expressing cancer cell mitoses. Interestingly, the impact of diffuse separase expression on patient outcome was inversed, that is, lack of diffuse separase indicated 1.8-fold risk of breast cancer death (*P*=0.0006) as compared with diffuse separase-positivity. Again, a significant survival difference could be detected so that the majority (\>75%) of patients lacking diffuse separase expression in their breast carcinomas lived 7.6 years longer than the patients with carcinomas showing diffuse separase positivity. Both mitotic and diffuse separase expressions also predicted significantly impaired disease-specific outcome among the subgroup of luminal breast carcinomas (HR 1.3, *P*=0.02 and HR 2.9, *P*\<0.0001, respectively). Instead, we could not detect prognostic value in TNBC or HER2-amplified carcinomas, possibly due to the small number of patients in these subgroups. In multivariate analyses, both mitotic separase and loss of diffuse separase expression showed independent prognostic value among all breast carcinomas ([Table 2](#tbl2){ref-type="table"}). In summary, our results suggest that patients with high mitotic separase have unfavourable prognosis, whereas patients with diffuse separase have survival advantages. High rate of mitotic separase may be seen to reflect high proliferative activity, which is a known feature of aggressive behavior in malignant disease, especially as separase overexpression has been shown to promote aneuploid cell divisions and genetic heterogeneity ([@bib42]). The association of diffuse separase with favourable prognosis remains unsettled but has been suggested to reflect the activity of separase where auto-cleavage of separase may have a role ([@bib42]). Separase protein overexpression has been demonstrated in several human malignancies, including breast carcinomas, osteosarcomas, glioblastomas and chronic myeloid leukaemias ([@bib19]; [@bib24]; [@bib20]). Previously, separase expression has been associated with relapse, metastasis and/or survival in prostate cancers and glioblastoma ([@bib19]; [@bib20]). In breast carcinoma, separase RNA levels have been associated with metastatic disease, especially for Luminal B subtype ([@bib19]; [@bib5]). To our knowledge, there are no previous reports on the association of separase to breast cancer survival. Also separase gene expression, as evaluated in a meta-selection, has been associated with carcinogenesis and prognosis in several solid tumours ([@bib30]).

Separase is a multifunctional protein that has been under intensive research as its discovery ([@bib37]). The functions of separase in oncogenesis and tumour progression as well as in both mitotic and meiotic divisions have been well established ([@bib42]). When the sister kinetochores are bioriented in metaphase, separase participates in the proteolytical cleavage of cohesion, which ultimately triggers the separation of the sister chromatids. This transition from metaphase to anaphase is controlled by the APC/C ([@bib27]). In previous literature, the spatial localisation of separase has been reported to vary with the progression of the cell cycle so that in interphase separase is localised in the cytoplasm whereas during mitosis it accumulates in the nucleus and associates with chromosomes ([@bib42]). Abnormal function of separase has been associated with aneuploidy and genetic instability inducing subsequent tumourigenesis. Transgenic mice expressing the MMTV-separase cDNA have been shown to develop aneuploidy and highly aggressive and heterogeneous mammary adenocarcinomas of both luminal and basal subtypes ([@bib21]). Both cyclin B1 and securin are known to essentially regulate the separase-dependent events in metaphase--anaphase transition ([@bib2]). Previous literature has addressed mitotic slippage, that is, the escape of mitosis-incompetent cells from mitotic arrest, as one possible mechanism by which the normally controlled sequence of degradation of cyclin B1 and/or securin may be overridden at the metaphase--anaphase transition ([@bib36]). However, there are numerous hypotheses on the role of separase in aberrant cell expression ([@bib14]). In our double-IFs, we saw different expression patterns for separase, securin and cyclin B1. Typically, separase-positive cells co-expressed cyclin B1 but not securin, a finding consistent with the expedient pattern of normal separase-dependent cell cycle control. However, as observed in our triple-IFs at a single-cell level, an aberrant expression pattern seen in some carcinomas with aggressive morphology may reflect abnormal cell cycle control driving aneuploidy and chromosomal instability, both common features in high-grade breast carcinomas and especially TNBC. In mouse mammary epithelium, the transcriptional regulation of separase expression has been shown to be facilitated by loss of p53 and induced by ER and PR ([@bib26]). These observations are in line with the general understanding that misregulated sister chromatid segregation favours aneuploidy and drives proliferation in aggressive breast carcinomas ([@bib19]; [@bib40]).

In malignant disease, separase has been described showing different expression patterns and subcellular localisations reflecting the numerous roles of separase in oncogenesis ([@bib42]). Previously, not only the total cellular level of separase but also its subcellular expression patterns have been reported to vary between normal tissue and different stages of malignancy. Previously in literature, however, only nuclear separase has been associated with tumour status in human carcinomas, including breast cancer ([@bib19]). The exact expression patterns of separase and their prognostic associations have not previously been systematically described in breast cancer. Interestingly, we observed a prognostic impact associated with translocation of separase from the cytoplasm to the mitotic nucleus. As a new finding, diffuse separase observed in the cancer cells independently predicted breast cancer outcome in our material. According to experiments in budding yeast, securin is responsible for separase being translocated into the nucleus and, in DNA damage, prevents the cell from progressing to anaphase ([@bib12]). It has been proposed that separase might be important in DNA damage repair ([@bib23]). However, the connection of overexpression and subcellular localisation of separase to tumour formation and/or progression is not yet understood. These observations suggest the hypothesis that misregulation of sister chromatid segregation by hyperactive separase induces chromosomal instability and aneuploidy, common features in TNBC ([@bib1]; [@bib21]; [@bib40]). Our findings from double- and triple-IFs also demonstrate the abnormal regulation of separase and emphasise the independent role of separase in driving proliferation.

Currently, molecular subtyping is the basis for breast cancer diagnostics and treatment, proliferation being one of the routine indicators for disease aggressiveness. In spite of the advent of molecular testing, intrinsic classification based on surrogate markers, including proliferation, is still the basis of breast cancer classification and treatment decisions, particularly in case of the luminal B subtype ([@bib28]; [@bib17]). Moreover, traditional histological grade and the Nottingham Grading Index are considered among the most accurate methods to assess the biological characteristics and patient survival in breast cancer ([@bib29]; [@bib32]). Both surrogate criteria of the intrinsic classification and histological grading, however, involve mitotic counting, which is considered a laborious and time consuming method ([@bib4]). Also, the routine proliferation markers of clinical pathology, that is, Ki-67 and PHH3 IHC do not provide optimal prognostic information for breast cancer. Ki67-IHC is often considered difficult to interpret due to its heterogeneity and varying intensity ([@bib13]). The interpretation of PHH3-IHC is a more solid but the detection method is particularly susceptible to poor fixation. In our experience, detection and interpretation of separase-positive mitoses is easy and reproducible. Based on uni- and multivariate survival analyses, our results also demonstrate the superior prognostic value of separase to histological grading and Ki-67.

In summary, our findings from 349 human breast carcinomas with maximum of \>22 years of follow-up show that separase is a potential prognosticator with independent value in identifying disease-specific survival. As a proliferation marker, separase-IHC is well applicable to clinical routine and shows practical and prognostic value over PHH3 and Ki-67. Our observations on double- and triple-IFs suggest that aberrant expression patterns of separase and its regulating proteins, securin and cyclin B1, identify patients with particularly aggressive subtypes of breast carcinoma. In all, we suggest that separase could be developed into a beneficial biomarker for treatment decisions and a potential therapeutic target for breast carcinoma.
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###### 

Click here for additional data file.

![**Examples of separase immunoexpression in invasive breast carcinomas and benign breast epithelium.** Separase positivity was observed as two distinct staining patterns in the cancer cells, diffuse separase expression in the cytoplasm and nucleus, and mitotic separase. Benign breast tissue showed a clear diffuse separase expression and only single separase-positive mitoses reflecting the low proliferation rate in normal breast epithelium (**A**). In breast carcinomas representing luminal (**B**), HER2-amplified (**C**) and triple-negative breast carcinomas (**D**), the two staining patterns occurred inversely related so that strong diffuse separase-positivity was associated with low mitotic separase-expression and vice versa. (magnification × 400, space bar 100 *μ*m). A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017301f1){#fig1}

![**Immunostaining of separase with established and experimental markers of proliferation in breast carcinoma.** Double-IF stainings were performed for combinations of separase (green) with Ki-67, PHH3 and securin (red). In all double-IFs, separase showed co-expression in proliferating cells but the association was most clear between separase and PHH3. Double-IF for separase (red) and Cleaved casepase-3 (green) showed that separase was not expressed in apoptotic cells. (magnification × 400). A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017301f2){#fig2}

![**Kaplan--Meier curves of breast cancer-specific survival showing the survival difference of breast carcinoma patients associated with mitotic (\<1% *vs* ⩾1% of cancer cells) and diffuse separase expression (negative *vs* positive cancer cells).** The figures show survival among all patients (**A**, **C**) and among patients with luminal carcinoma (**B**, **D**). The figures also show survival difference for the majority (75%) of patients in both prognostic groups (dashed lines).](bjc2017301f3){#fig3}

![**Double- and triple-IFs demonstrate the co-localisation and distribution of separase with securin and cyclin B1 in invasive breast carcinomas.** The co-expression patterns for separase and securin, and separase and cyclin B1 were similar in benign breast epithelium and in the majority of carcinoma cells that is, separase-positive cells typically co-expressed cyclin B1 but not securin (**A**). In some carcinomas of aggressive morphology, however, we observed an aberrant expression pattern where cancer cells either co-expressed separase and securin or, alternatively, showed only separase positivity (**A**). These aberrant expression patterns were also verified in triple-IFs showing cancer cells with either simultaneous expression of the three markers or separase expression alone (**B**). (magnification × 400). A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017301f4){#fig4}

###### Summary of double-IF[a](#t1-fn1){ref-type="fn"} and triple-IF[b](#t1-fn2){ref-type="fn"} staining methods

                                                                                                                   **cyclin B1**                      
  --------------------------- -------------------------------------------- --------------------------------------- ---------------------------------- ------------------
  **Antibody** **staining**   **Separase** **double- and triple-IF**       **Securin** **double- and triple-IF**   **Double-IF**                      **Triple-IF**
  Type                        Mouse monoclonal                             Rabbit monoclonal                       Rabbit monoclonal                  mouse monoclonal
  Clone                       6H6                                          EPR3240                                 Y106                               V152
  Source                      Novus Biologicals H00009700-M01              Abcam ab79546                           Abcam ab32053                      MA5-13128
  Dilution                    1:100 or 1:1600[c](#t1-fn3){ref-type="fn"}   1:500 1h RT                             1:100 1h RT                        1:600 1h RT
  **Antibody**                **Ki-67**                                    **PHH3**                                **Cleaved caspase-3**               
  **Staining**                **double-IF**                                **double-IF**                           **double-IF**                       
  Type                        Rabbit polyclonal                            Rabbit polyclonal                       Rabbit monoclonal                   
  Clone                       Polyclonal                                   Polyclonal                              D3E9                                
  Source                      Chemicon International AB9260                Cell Marque 369A-14                     Cell Signaling Technology \#9579    
  Dilution                    1:1000                                       1:100                                   1:100                               

Tyramide Signal Amplification HRP Kit, Molecular Probes by LifeTechnologies, Eugene, OR, USA.

Goat Anti-Mouse IgG2a Human ads-HRP, 1080-05, SouthernBiotech, Birmingham, AL, USA. Tyramide Signal Amplification HRP Kit, Molecular Probes by LifeTechnologies, Eugene, OR, USA. Goat Anti-Mouse IgG1 Human ads-HRP, 1070-05, SouthernBiotech, Birmingham, AL, USA.

Dilutions and incubations times and temperatures were optimised for each lot of antibody.

###### Multivariate analyses for mitotic and diffuse separase expressions, and the established prognosticators of invasive breast carcinoma[a](#t2-fn2){ref-type="fn"}

                        **HR**   ***P***     **CI**
  -------------------- -------- ---------- ----------
  Mitotic separase       1.6       0.03     1.0--2.5
  Tumour size            2.1      0.001     1.3--3.3
  Histological grade                NS          
  Nodal status           3.2     \<0.0001   2.1--4.8
  Diffuse separase       1.8      0.002     1.2--3.8
  Tumour size            2.2      0.0006    1.4--3.5
  Histological grade                NS          
  Nodal status           3.2     \<0.0001   2.1--4.9

Abbreviations: CI=95% confidence interval; HR=hazard ratio; NS=no statistical significance; *P*=*P*-value of Cox's proportional hazard model. The analysis is based on 349 breast carcinoma statistically patients with up to 22-year follow-up. Only analyses with signicificant associations are shown.

Analysis has been performed on material divided into groups with favourable *vs* unfavourable prognosis as follows: Mitotic separase comparing low *vs* high expression (\<1% *vs* ⩾1% separase-positive mitoses in cancer cells). Diffuse separase comparing positive (intensity 1+ −2+) *vs* negative (0) expression in carcinoma cells. Tumour size stratified into small *vs* large (⩽2 cm *vs* \>2 cm in diameter). Nodal status startified into axillary lymph node negative *vs* positive. Histological grade compared between 1--2 and 3.
